Virbac SA is an independent pharmaceutical company dedicated to animal health, founded in 1968. The company develops and markets a comprehensive range of products for the diagnosis, prevention, and treatment of diseases in companion animals, farm animals, and aquaculture species. Its portfolio includes vaccines, parasiticides, dermatological solutions, dental care products, and nutritional supplements. Virbac serves veterinarians, farmers, and pet owners globally, operating production units and R&D centers across five continents. Key subsidiaries include Virbac France, Virbac Nutrition, Allerderm, Imperial Dog, Agri-Nutrition, Agrivet Farm Care, Centrovet, and Schweitzer Biotech. The company maintains scientific partnerships with international research laboratories and has acquired assets in the United States, India, Chile, and Taiwan to expand its global presence and product offerings.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Drug Manufacturers - Specialty & Generic Homepage corporate.virbac.com
Sector Healthcare IR page corporate.virbac.com/home/investors
Tags
animal health, veterinary vaccines, parasiticides, dermatology, aquaculture, farm animal health, companion animal care, nutritional supplements, dental care, biotechnology, Virbac France, Virbac Nutrition, Allerderm, Imperial Dog, Agri-Nutrition, Agrivet Farm Care, Centrovet, Schweitzer Biotech, Virbac Thailand, Target 150
Press page —

Metrics

Valuation  
Market cap € 3.058B
Market cap (USD) $ 3.403B
P/E 20.27
PEG 2.76
P/BV 2.72
P/S 2.09
P/OCF 15.37
P/FCF 28.65
Dividend yield 0.36%
Turnover / mcap —
Returns  
ROE 13.9%
ROI 11.8%
ROIC 12.2%
Profit margin 10.3%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 7.4%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity 13.4%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 25
Quality score 27.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Revenue 1.465B 1.397B 1.247B 1.216B 1.064B 934.198M -2.074M — — — — — — — — —
Net profit 150.887M 145.29M 121.298M 121.967M 113.162M 136.039M 8.766M 20.985M 1.759M 37.867M 12.668M 70.533M 69.009M 67.202M 58.555M 64.313M
Free cash flow 106.754M 134.975M 77.599M 60.241M 96.252M 96.46M — — — — — — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Share price — 365.04 262 — 412 234.96 — — — — — — — — — —
Price performance 12m — 0.39 — — 0.75 — — — — — — — — — — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (EUR) — 102M 107M 146M 168M 196M 201M
↳ YoY growth +5.6% +36.3% +14.8% +16.7% +2.6%
↳ 5y CAGR +14.6%
Other receivables (EUR) — 67.8M 72.2M 65.4M 85.3M 89.9M —
Borrowings, current (EUR) — — — — — 58M 106M
Borrowings, non-current (EUR) — — — — — 222M 150M
Lease liabilities (EUR) — 34.8M 38.5M 36.8M 35.1M 38.1M 39M
Cash and deposits (EUR) 93.7M 182M 173M 177M 176M 150M 123M
Intangible assets (EUR) — 145M 149M 154M 185M 251M 231M
Right-of-use assets (EUR) — 33.5M 36.5M 34.6M 32.9M 36.9M 37.6M
Net debt (borrowings + leases - cash) (EUR) — — — — — 169M 173M
Cash flow detail
Operating cash flow (EUR) — 119M 130M 99M 119M 204M 199M
Purchases of property, plant and equipment (EUR) — -22.5M -33.7M -38.7M -41M -69.2M -92.2M
Purchases of intangible assets (EUR) — -6.53M -13.5M -14.8M -18.9M -11.2M -9.9M
Change in receivables (cash effect) (EUR) — -7.63M -5.62M -37.8M -22M -4.89M -15.7M
Change in inventories (cash effect) (EUR) — -22.1M -54.3M -55.8M -9.03M -20.9M 4.2M
Change in payables (cash effect) (EUR) — 12.1M 18.7M 25.4M -9.94M 4.08M 11.9M
Dividends paid (cash effect) (EUR) — 0.00 -6.34M -10.6M -11.2M -11.1M -12.1M
Interest paid (cash effect) (EUR) — — — — -159,000 -4.73M -4.27M
Income taxes paid (cash effect) (EUR) — -30.2M -52.9M -75.4M -61.5M -44.9M -77.9M
Operating cash flow before change in receivables (EUR) — 127M 136M 137M 141M 209M 215M
Free cash flow (OCF - PPE - intangibles) (EUR) — 89.9M 82.7M 45.4M 58.7M 124M 96.9M
Income detail
Total comprehensive income (EUR) — 106M 137M 126M 107M 148M 91.3M
Comprehensive income to owners (EUR) — 102M 136M 127M 107M 148M 91.7M
Reported Apr 28, 2022 Apr 28, 2022 Apr 28, 2022 Apr 26, 2023 Apr 28, 2025 Apr 27, 2026 Apr 27, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Virbac SA (ticker VIRP), listed in France.

ETFs Holding Virbac SA

ETF Weight in ETF Shares Market value As of
AVDS 0.07% 677 $ 264.186K Nov 16, 2026
DFIS 0.05% 7,450 $ 2.947M Nov 12, 2026
AVSD 0.02% 224 $ 87.412K Nov 16, 2026
DXIV 0.02% 120 $ 47.475K Nov 12, 2026
AVDE 0.01% 2,507 $ 978.309K Nov 16, 2026
DFIC 0.01% 3,754 $ 1.485M Nov 12, 2026
DFSI 0.01% 195 $ 77.147K Nov 12, 2026
DFAI 0.01% 2,661 $ 1.053M Nov 12, 2026
DFAX 0.01% 1,722 $ 681.269K Nov 12, 2026